Efficacy News and Research

RSS

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject (diclofenac sodium) Injection, a proprietary nonsteroidal anti-inflammatory drug (NSAID) analgesic.

30 Dec 2014

MagnaChip launches new bio-sensor research collaboration

MagnaChip Semiconductor Corporation, a Korea-based designer and manufacturer of analog and mixed-signal semiconductor products, today announced it has launched a research collaboration focused on developing innovative, cost-effective silicon magnetic bio-sensor technology capable of monitoring extremely rare cells in blood.

30 Dec 2014

Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program.

29 Dec 2014

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Kinex Pharmaceuticals announced today that the first patient has been dosed with KX2-361 at Roswell Park Cancer Institute.

25 Dec 2014

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.

25 Dec 2014

Transcranial direct current stimulation can help modify attention to threat

Transcranial direct current stimulation (tDCS) is a painless treatment strategy that uses weak electrical currents to deliver targeted stimulation to the brain via electrodes placed on the scalp. tDCS has shown promise in treating mood, anxiety, cognition, and some symptoms of Parkinson's disease.

24 Dec 2014

Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLC

Mirati Therapeutics, Inc. today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a Phase 1b clinical trial of MGCD265 in selected patients exhibiting genetic alterations of MET or Axl.

23 Dec 2014

EB Pharma licenses tipifarnib from Janssen to study potential new therapy for HDV

EB Pharma, LLC., a subsidiary of Eiger BioPharmaceuticals, Inc., announced that it has executed an agreement with Janssen Pharmaceutica NV, for an exclusive license, to tipifarnib in the field of virology and a related, clinical stage back-up compound.

23 Dec 2014

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

AbbVie receives Health Canada approval for HOLKIRA PAK (ombitasvir/paritaprevir/ritonavir film-coated tablets; dasabuvir film-coated tablets), an all-oral, short-course (12 weeks for the majority of patients), interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with cirrhosis.

23 Dec 2014

First two patients enrolled in AGA’s GERD Registry successfully undergo treatment

The American Gastroenterological Association (AGA) Center for GI Innovation and Technology is pleased to announce that the first two enrollees in the STAR Registry — which seeks to compare laparoscopic surgery to an incisionless procedure to treat gastroesophageal reflux disease (GERD) — have successfully undergone treatment.

23 Dec 2014

AGA) Center for GI Innovation and Technology is pleased to announce that the first two enrollees in the STAR Registry

23 Dec 2014

Cell-associated HIV transmission contributes to HIV epidemic

Dr. Deborah Anderson from Boston University School of Medicine (BUSM) and her colleagues are challenging dogma about the transmission of the human immunodeficiency virus type 1 (HIV-1).

22 Dec 2014

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

22 Dec 2014

Special issue of Technology and Innovation publishes proceedings of annual NAI conference

The current special issue of Technology and Innovation, is devoted to presentations from the Third Annual Conference of the National Academy of Inventors (NAI), which was held Mar. 6-7, 2014, at the headquarters of the United States Patent and Trademark Office (USPTO) in Alexandria, Va.

22 Dec 2014

Novo Nordisk gets positive CHMP opinion for expanded use of Tresiba in children with diabetes

Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba® (insulin degludec) in children and adolescents aged one to 17 years with diabetes.

From Novo Nordisk 22 Dec 2014

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis.

21 Dec 2014

Oral budesonide suspension offers hope for pediatric patients with EoE

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

19 Dec 2014

Canopus BioPharma study confirms efficacy of CB008 drug for Ebola Virus inhibition

Canopus BioPharma Inc. today announces that it has completed crucial research in confirming efficacy of a prescription drug: CB008 for Ebola Virus inhibition.

19 Dec 2014

High speed, high resolution glycan mapping now achievable for mAb characterization

The full characterization of biotherapeutics is required by regulatory authorities as properties such as safety, efficacy and the serum half-life of therapeutic proteins can be affected by differences in their glycosylation pattern. Recombinant monoclonal antibody therapeutics (mAbs) represent the largest group of therapeutic proteins the analysis of the glycan pattern is therefore an essential part of the mAb characterization process.

19 Dec 2014

$Nuvo Research completes WF10 Phase 2 trial in patients with refractory allergic rhinitis$

Nuvo Research completes WF10 Phase 2 trial in patients with refractory allergic rhinitis

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of immunology and topical products, today announced that 179 patients have completed its 16-week, double-blind, placebo-controlled, Phase 2 clinical trial to investigate the safety and efficacy of WF10 in patients with refractory allergic rhinitis.

18 Dec 2014

Efficacy News and Research

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

MagnaChip launches new bio-sensor research collaboration

Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Transcranial direct current stimulation can help modify attention to threat

Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLC

EB Pharma licenses tipifarnib from Janssen to study potential new therapy for HDV

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

First two patients enrolled in AGA’s GERD Registry successfully undergo treatment

AGA) Center for GI Innovation and Technology is pleased to announce that the first two enrollees in the STAR Registry

Cell-associated HIV transmission contributes to HIV epidemic

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Special issue of Technology and Innovation publishes proceedings of annual NAI conference

Novo Nordisk gets positive CHMP opinion for expanded use of Tresiba in children with diabetes

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

Oral budesonide suspension offers hope for pediatric patients with EoE

Canopus BioPharma study confirms efficacy of CB008 drug for Ebola Virus inhibition

High speed, high resolution glycan mapping now achievable for mAb characterization

Nuvo Research completes WF10 Phase 2 trial in patients with refractory allergic rhinitis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News